Clinical Trial Update: Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update assessing the safety and HIV-1 expression effects of the HDAC inhibitor panobinostat in patients on suppressive antiretroviral therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: University of Aarhus | Conditions: HIV Infection | Phase 1, Phase 2 | Status: COMPLETED